Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $125.00. The company’s shares closed yesterday at $99.65.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

Here are some before and after pictures of the company's wordmark and logo. Need a break? Play the USA TODAY Daily Crossword Puzzle. Here's a look at how the new wordmark and logo will appear on ...

Walmart is refreshing its logo for the first time in nearly two decades, highlighting its evolution while also serving as a nod to its past, the big-box retailer announced Monday. The word mark on ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of $150.00. Discover outperforming stocks and invest smarter with ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...